Shares of Corvus Pharmaceuticals Inc. (CRVS) gained 39.1% in premarket trading on Monday after the company shared additional interim details from a very small, early-stage clinical trial that indicates its experimental immunotherapy could produce antibodies and T-cells in some COVID-19 patients. The open-label, Phase 1 study has tested at three doses in 15 patients and plans to enroll a total of 30 patients with mild to moderate forms of the disease. A preprint ( ) published in September had outlined initial results for two of the doses in 10 patients. (A preprint has not been peer-reviewed.) The company on Monday released data for five additional patients. Full results from the Phase 1 trial are expected to be released before the end of the year. Corvus' stock is down 25.2% so far this year, while the S&P 500 has gained 3.6%.
-Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com
(END) Dow Jones Newswires
October 05, 2020 08:05 ET (12:05 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.